Opioid-Induced Constipation Significant in Pain Patients

This article originally appeared here.
Share this content:
Opioid-Induced Constipation Significant in Pain Patients
Opioid-Induced Constipation Significant in Pain Patients

TUESDAY, March 31, 2015 (HealthDay News) -- Opioid-induced constipation (OIC) is significant among noncancer pain patients, according to a study published online March 20 in Pain Medicine.

Karin S. Coyne, Ph.D., M.P.H., from Evidera in Bethesda, Md., and colleagues evaluated patients (62 percent female; 85 percent white) on opioid therapy for at least four weeks for chronic noncancer pain. OIC was assessed using an Internet-based survey at baseline (489 patients) and weeks 2, 4, 6, 8, 12, 16, 20, and 24. Sufficient laxative use (at least one laxative at least four times in past two weeks) and inadequate response (LIR; fewer than three bowel movements or at least one constipation symptom rated moderate or greater) defined 1xLIR, while 2xLIR was defined as sufficient laxative use of at least two laxatives from different drug classes and inadequate response.

The researchers found that at baseline, 27 percent of participants reported no laxative use, 25 percent had insufficient laxative use, and 48 percent had sufficient laxative use. Over the follow-up, 21 to 28 percent of patients had no or insufficient laxative use. At baseline, the prevalence of 1xLIR was 93 percent; it ranged from 59 to 81 percent across follow-up. For 2xLIR, 26 percent met criteria at baseline, while the range during follow-up was 11 to 20 percent.

"OIC among noncancer pain patients is a persistent and significant condition with varying utilization and response to laxatives thus increasing the ongoing burden of chronic pain," the authors write.

Three authors disclosed financial ties to AstraZeneca, which funded the study. Other authors disclosed ties to Evidera and United BioSource Corporation.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »